Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile

• Main Authors: Pavel Jansa, Samuel Heller, Michal Svoboda, Michal Pad’our, David Ambrož, Vladimír Dytrych, Michal Širanec, Tomáš Kovárník, Marián Felšőci, Martin Hutyra, Aleš Linhart, Jaroslav Lindner, Michael Aschermann
• Format: Article
• Language: English
• Published: MDPI AG 2020-11-01
• Series: Journal of Clinical Medicine
• Subjects: chronic thromboembolic pulmonary hypertension; balloon pulmonary angioplasty; efficacy; safety; quality of life; risk profile
• Online Access: https://www.mdpi.com/2077-0383/9/11/3608

Balloon pulmonary angioplasty (BPA) is a novel treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are not eligible for pulmonary endarterectomy (PEA) or suffer from persistent pulmonary hypertension after PEA. The aim of this study was to evaluate the real-life efficacy and safety of BPA in a consecutive group of patients who were diagnosed and treated in the national referral center for CTEPH in the Czech Republic. Here we report data from 160 BPA procedures performed in 64 patients. Efficacy analysis was performed in the subgroup of 25 patients who completed BPA series. Significant improvements were observed in New York Heart Association functional class (4% to 79% in I/II, <i>p</i><i> </i>< 0.001), 6 min walking test distance (+54.3 m, <i>p</i> < 0.001), risk profile (15.8% to 68.5% with presence of 2/3 low risk criteria, <i>p</i> < 0.001), pulmonary artery mean pressure (−18%, <i>p </i>< 0.001), pulmonary vascular resistance (−32%, <i>p </i>< 0.001), stroke volume (+17%, <i>p</i> = 0.011) and quality of life (+37% in assessment of overall health status by a patient, <i>p</i> < 0.001). We observed 1 fatal periprocedural complication (1.6% of all 64 patients) and 19 BPA-related non-fatal complications (11.9% of all 160 interventions) that predominantly included hemoptysis (10.0% of all sessions). Overall survival at 12 months was 94.6%.